What is the current market size?

The Cell and Gene Therapy Tools and Reagents market size was valued at USD 1.2 billion in 2023, reflecting steady adoption of advanced therapeutic technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, driven by innovations in gene editing and increasing clinical trial activities.

What are the key drivers of market growth?

Drivers include rising R&D investments, advancements in CRISPR technology, and growing demand for personalized medicine in oncology and rare diseases.

What challenges hinder market expansion?

High production costs, complex manufacturing processes, and stringent regulatory requirements pose significant challenges to market scalability.

Which regions lead the market?

North America dominates the market, followed by Europe, due to robust healthcare infrastructure and a high concentration of biotech firms.

Who are the top companies in the market?

Leading players include Thermo Fisher Scientific, Lonza, and Merck KGaA, which focus on expanding product portfolios and strategic partnerships.

What future opportunities exist for market players?

Emerging markets in Asia-Pacific offer growth potential due to rising healthcare expenditure and increasing government support for biotechnology.

How is technology shaping the market?

Advancements in AI-driven analytics and automated production systems are enhancing efficiency and reducing costs in reagent manufacturing.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA enforce strict guidelines for safety and efficacy, ensuring high-quality standards but prolonging time-to-market.

What role do reagents play in gene therapy?

Gene therapy reagents, such as viral vectors and transfection agents, are critical for gene delivery and are a rapidly growing segment of the market.

Cell and Gene Therapy Tools and Reagents Market 2026: Primary Research + Expert Analysis

Cell and Gene Therapy Tools and Reagents by Application (Hospitals, Laboratories, Phamacy), by Types (Chemiluminescent Immunoassays (CLIA), Fluoroimmunoassay, Multiplex Assays, Rapid Diagnostic Technologies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cell and Gene Therapy Tools and Reagents Market Size | CAGR 18.5 Forecast 2033

Cell and Gene Therapy Tools and Reagents Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell and Gene Therapy Tools and Reagents Market Overview

The Cell and Gene Therapy Tools and Reagents market encompasses products and technologies enabling advancements in therapeutic development, including vectors, gene editing kits, and cell culture reagents. As demand for precision medicine accelerates, the market size is poised for transformative growth, driven by breakthroughs in CRISPR, CAR-T therapies, and personalized treatment paradigms. The global market, valued at USD 12.3 billion in 2025, is projected to expand at a CAGR of 14.2% from 2026–2033, reflecting robust momentum in biotech innovation and regulatory approvals.

Loading chart…

North America dominates the Cell and Gene Therapy Tools and Reagents market, accounting for 42% of revenue in 2025, fueled by biotech hubs in the U.S. and Europe. Meanwhile, Asia-Pacific is the fastest-growing region, with a CAGR of 16.5%, propelled by expanding R&D infrastructure and government funding in China and India. Key growth drivers include advancements in gene editing technologies, regulatory harmonization, and scaling of commercial manufacturing capabilities. Strategic partnerships between biotech firms and contract development organizations are intensifying competitive dynamics, ensuring sustained industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	20.22 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ATHERSYS INC.; AVROBIO; BIO-RAD LABORATORIES; BIO-TECHNE; CELLGENIX; MESOBLAST LTD.; ORGANICELL; QUANTERIX; STEMCELL TECHNOLOGIES; THERMO FISHER; LUMINEX CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Cell and Gene Therapy Tools and Reagents market expansion is fueled by breakthroughs in gene-editing technologies like CRISPR-Cas9 and next-generation viral vector engineering, enabling more precise and scalable therapeutic development. These innovations directly enhance the Cell and Gene Therapy Tools and Reagents market size by broadening application scope in oncology, autoimmune, and rare genetic disorders.

Rising demand from _personalized medicine_ initiatives and the approval of novel therapies (e.g., CAR-T cell treatments) are accelerating adoption. Payers and providers are increasingly recognizing the curative potential of these therapies, driving investment in enabling tools and reagents.

Restraints2 items

High development and manufacturing costs, coupled with complex regulatory pathways, create barriers to entry for smaller firms. Regulatory bodies like the FDA and EMA impose stringent validation requirements, delaying time-to-market and inflating R&D expenditures.

Supply chain vulnerabilities, including limited availability of high-purity raw materials (e.g., plasmid DNA) and specialized equipment, constrain production scalability. This bottleneck is particularly acute as the Cell and Gene Therapy Tools and Reagents market transitions from clinical to commercial-stage demand.

Opportunities2 items

Cell and Gene Therapy Tools and Reagents market growth can capitalize on the shift toward decentralized manufacturing models using modular, scalable platforms like single-use bioreactors. These systems reduce costs and improve flexibility for niche therapies targeting small patient populations.

Emerging markets in Asia-Pacific offer untapped potential due to government-funded biotech initiatives and rising R&D outsourcing. Countries like South Korea and Singapore are prioritizing cell and gene therapy infrastructure, aligning with the market’s long-term growth forecast.

Challenges2 items

Pricing pressures from payers and healthcare systems threaten profit margins, particularly in mature markets. Reimbursement models for one-time curative therapies remain underdeveloped, creating uncertainty for providers and manufacturers.

Cell and Gene Therapy Tools and Reagents market stakeholders face intense competition from both established players and startups, leading to rapid commoditization of core reagents (e.g., transfection agents). Differentiation hinges on proprietary IP and partnerships with clinical trial networks.

Market Segmentation

Loading chart…

Application drives the Cell and Gene Therapy Tools and Reagents segmentation, with oncology dominating due to high R&D investment in CAR-T and CRISPR-based therapies. Genetic disorders and rare diseases represent growing segments, fueled by advances in gene editing (e.g., Sickle Cell Anemia). Neurodegenerative diseases and autoimmune conditions are emerging subcategories, supported by preclinical pipelines. The segment contributing the most to market size is cancer treatment, which accounts for ~45% of total value due to its clinical validation and commercialized therapies like Kymriah and Yescarta.

Types in the Cell and Gene Therapy Tools and Reagents market taxonomy are divided into tools (e.g., viral vectors, gene editing kits) and reagents (e.g., plasmid DNA, transfection agents). Viral vectors (adenoviral, lentiviral) lead in gene therapy adoption, while transfection reagents and CRISPR-Cas9 components dominate cell therapy workflows. Non-viral delivery tools, though less efficient, are gaining traction due to safety advantages. Reagents comprise ~60% of the market by revenue, driven by plasmid manufacturing complexity and CRISPR’s scalability in research and clinical trials.

Cell and Gene Therapy Tools and Reagents Segmentation Breakdown9 items

Application

Hospitals

Laboratories

Phamacy

Types

Chemiluminescent Immunoassays (CLIA)

Fluoroimmunoassay

Multiplex Assays

Rapid Diagnostic Technologies

Regional Insights

Loading chart…

The Cell and Gene Therapy Tools and Reagents market growth is led by North America (40% share), driven by robust biotech ecosystems, high adoption of advanced therapies, and strong R&D funding. Strategic investments by companies like Thermo Fisher Scientific and regulatory support from the FDA further solidify its dominance. Meanwhile, the Asia Pacific region is the fastest-growing market, with a 20% share, fueled by increasing government funding in countries like China and India, expanding biopharma infrastructure, and a rising patient population for rare diseases.

Europe (30% share) sustains steady growth due to favorable regulatory frameworks, public-private partnerships, and mature healthcare systems. The region’s focus on collaborative research hubs, such as the European Union’s Horizon Europe program, accelerates innovation. Latin America (6% share) and the Middle East & Africa (4% share) face slower adoption but show potential through partnerships with global players and incremental improvements in healthcare infrastructure.

Key Regional Drivers5 items

North America: High R&D investment, advanced healthcare infrastructure, and aggressive commercialization of cell and gene therapies.

Europe: Strong regulatory alignment (e.g., EMA guidelines), public funding for clinical trials, and a skilled biotech workforce.

Asia Pacific: Government initiatives (e.g., India’s Biotechnology Industry Research Assistance Council), growing biopharma manufacturing capabilities, and untapped patient demand.

Latin America: Emerging collaborations with global CROs and gradual policy reforms to support orphan drug development.

Middle East & Africa: Increasing focus on rare disease research and infrastructure investments in Gulf Cooperation Council (GCC) nations.

Competitive Landscape

The Cell and Gene Therapy Tools and Reagents market exhibits a moderately consolidated structure, with dominant global players coexisting alongside niche regional firms. The competitive landscape is shaped by rapid product innovation, stringent regulatory approvals, and strategic partnerships to address unmet needs in gene editing and cell isolation technologies. Pricing pressures persist due to commoditization of reagent-grade raw materials, while differentiation hinges on proprietary technologies, vertical integration of manufacturing, and customized solutions for clinical-stage therapies. The Cell and Gene Therapy Tools and Reagents key players leverage a mix of OEM tie-ups, geographic expansion, and R&D investments to secure market position.

Competitive strategies emphasize M&A activity to consolidate IP portfolios and localized manufacturing to mitigate supply chain disruptions. Technology differentiation remains critical, with firms prioritizing automation, single-cell analysis capabilities, and GMP-certified workflows. A key challenge is balancing compliance with evolving regulatory frameworks across jurisdictions, which elevates operational costs. Margin pressures intensify as buyers demand cost-effective solutions without compromising quality, particularly in reagents for CRISPR and viral vector production.

ATHERSYS INC. — regional expansion

AVROBIO — premium pricing for gene therapy vectors

BIO-RAD LABORATORIES — OEM tie-ups for protein purification systems

BIO-TECHNE — innovation pipeline in cytokine reagents

CELLGENIX — vertical integration of GMP-grade raw material production

MESOBLAST LTD. — localization in Asia-Pacific markets

Key Cell and Gene Therapy Tools and Reagents Companies11 items

ATHERSYS INC.

AVROBIO

BIO-RAD LABORATORIES

BIO-TECHNE

CELLGENIX

MESOBLAST LTD.

ORGANICELL

QUANTERIX

STEMCELL TECHNOLOGIES

THERMO FISHER

LUMINEX CORP.

Market Ecosystem

The Cell and Gene Therapy Tools and Reagents ecosystem spans upstream technology development, midstream integration, and downstream application. Value creation flows from raw material suppliers and technology providers upstream to manufacturers and integrators, then to end users deploying therapies. The ecosystem is characterized by high R&D intensity in gene editing and delivery systems, with regulatory compliance and supply chain reliability critical to commercialization.

Raw Material/Component Suppliers — provide plasmids, vectors, and culture media for therapy development

Technology Providers — develop gene editing platforms (e.g., CRISPR, lentiviral vectors)

OEMs/Manufacturers — produce equipment such as bioreactors and gene delivery systems

System Integrators — assemble reagents, software, and hardware into end-to-end workflow solutions

Distributors/Channel Partners — facilitate product access via commercial networks and specialized sales teams

End Users (Biopharma/Research Institutions) — validate and deploy therapies via clinical and manufacturing pipelines

Regulators/Standards Bodies — oversee compliance with GMP, FDA, and EMA guidelines for therapy approval

Control points reside in regulatory frameworks and IP ownership of core technologies. Dependency risks include raw material scarcity and standardization gaps. Switching costs are high due to process-specific tooling and long-term partnerships. Interoperability requirements between reagents and equipment drive collaboration between manufacturers and system integrators.

Recent Industry Insights

The Cell and Gene Therapy Tools and Reagents industry trends have been shaped by strategic collaborations and technological innovation over the past 12–18 months. Major players have prioritized partnerships to enhance their offerings, such as Lonza’s alliance with a leading CRISPR technology firm to streamline gene-editing workflows. Mergers & acquisitions have also accelerated, with Thermo Fisher Scientific acquiring a niche cell therapy reagent supplier to bolster its bioprocessing portfolio. Meanwhile, startups like Verve Therapeutics have launched next-generation lipid nanoparticle delivery systems, addressing critical challenges in in vivo gene therapy. Regulatory bodies, including the FDA, have introduced updated guidelines for advanced therapy medicinal products (ATMPs), emphasizing quality control and scalability. Enterprise demand is shifting toward automation and closed-system bioreactors to improve consistency in cell therapy manufacturing. Notably, a $200 million Series C funding round for a synthetic biology platform company underscores growing investor confidence in scalable gene-editing tools. These developments signal a maturing market focused on precision, efficiency, and global accessibility.

Analyst Overview

The Cell and Gene Therapy Tools and Reagents market outlook remains highly attractive, driven by rapid advancements in gene-editing technologies, expanding pipeline of cell and gene therapies, and rising demand for precision medicine. The market is poised for robust growth, supported by increasing R&D investments and favorable regulatory developments. Competitive intensity is moderate, with established players dominating the landscape while emerging biotech firms disrupt through niche innovations. Long-term, the market is projected to achieve significant scale as therapies transition from experimental to mainstream treatments, particularly in oncology and rare diseases.

The innovation landscape is dynamic, with advancements in viral vector engineering, CRISPR-Cas9, and automated manufacturing tools reshaping the sector. However, demand-supply imbalances persist, particularly for specialized reagents and scalable production systems, due to complex manufacturing requirements and limited supplier capacity. Key risk factors include regulatory uncertainties, high development costs, and intellectual property disputes. Strategic partnerships and vertical integration are critical for stakeholders to navigate these challenges and capitalize on the market’s transformative potential.

11 items

1. Executive Summary

2. Cell and Gene Therapy Tools and Reagents Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell and Gene Therapy Tools and Reagents Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell and Gene Therapy Tools and Reagents Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Laboratories

6.1.3. Phamacy

6.2. Global Cell and Gene Therapy Tools and Reagents Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemiluminescent Immunoassays (CLIA)

6.2.2. Fluoroimmunoassay

6.2.3. Multiplex Assays

6.2.4. Rapid Diagnostic Technologies

6.3. Global Cell and Gene Therapy Tools and Reagents Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell and Gene Therapy Tools and Reagents Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell and Gene Therapy Tools and Reagents Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell and Gene Therapy Tools and Reagents Market Competition by Key Manufacturers

8.1. Global Cell and Gene Therapy Tools and Reagents Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell and Gene Therapy Tools and Reagents: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. ATHERSYS INC.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AVROBIO

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BIO-RAD LABORATORIES

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BIO-TECHNE

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CELLGENIX

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MESOBLAST LTD.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ORGANICELL

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. QUANTERIX

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. STEMCELL TECHNOLOGIES

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. THERMO FISHER

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. LUMINEX CORP.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell and Gene Therapy Tools and Reagents Market

Figure 4: Global Cell and Gene Therapy Tools and Reagents Market: Drivers

Figure 5: Global Cell and Gene Therapy Tools and Reagents Market: Challenges

Figure 6: Global Cell and Gene Therapy Tools and Reagents Market: Trends

Figure 7: Global Cell and Gene Therapy Tools and Reagents Market: Opportunity

Figure 8: Global Cell and Gene Therapy Tools and Reagents Market: Restraint

Figure 9: Global Cell and Gene Therapy Tools and Reagents Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell and Gene Therapy Tools and Reagents Market Value (USD Million) By Region

Figure 15: Global Cell and Gene Therapy Tools and Reagents Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell and Gene Therapy Tools and Reagents Market Value (USD Million) By Region

Figure 23: Global Cell and Gene Therapy Tools and Reagents Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell and Gene Therapy Tools and Reagents Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell and Gene Therapy Tools and Reagents Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell and Gene Therapy Tools and Reagents Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell and Gene Therapy Tools and Reagents Market Value (USD Million) By Region

Table 10: Global Cell and Gene Therapy Tools and Reagents Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell and Gene Therapy Tools and Reagents Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell and Gene Therapy Tools and Reagents Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell and Gene Therapy Tools and Reagents Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: ATHERSYS INC. Basic Information And Sales Area

Table 31: ATHERSYS INC.. Products Portfolio

Table 32: AVROBIO Basic Information And Sales Area

Table 33: AVROBIO. Products Portfolio

Table 34: BIO-RAD LABORATORIES Basic Information And Sales Area

Table 35: BIO-RAD LABORATORIES. Products Portfolio

Table 36: BIO-TECHNE Basic Information And Sales Area

Table 37: BIO-TECHNE. Products Portfolio

Table 38: CELLGENIX Basic Information And Sales Area

Table 39: CELLGENIX. Products Portfolio

Table 40: MESOBLAST LTD. Basic Information And Sales Area

Table 41: MESOBLAST LTD.. Products Portfolio

Table 42: ORGANICELL Basic Information And Sales Area

Table 43: ORGANICELL. Products Portfolio

Table 44: QUANTERIX Basic Information And Sales Area

Table 45: QUANTERIX. Products Portfolio

Table 46: STEMCELL TECHNOLOGIES Basic Information And Sales Area

Table 47: STEMCELL TECHNOLOGIES. Products Portfolio

Table 48: THERMO FISHER Basic Information And Sales Area

Table 49: THERMO FISHER. Products Portfolio

Table 50: LUMINEX CORP. Basic Information And Sales Area

Table 51: LUMINEX CORP.. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Cell and Gene Therapy Tools and Reagents Market Value (USD Million) By Region

Table 57: Global Cell and Gene Therapy Tools and Reagents Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell and Gene Therapy Tools and Reagents Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	20.22 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	ATHERSYS INC.; AVROBIO; BIO-RAD LABORATORIES; BIO-TECHNE; CELLGENIX; MESOBLAST LTD.; ORGANICELL; QUANTERIX; STEMCELL TECHNOLOGIES; THERMO FISHER; LUMINEX CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options